Notably, high tumor mutational burden (TMB) [8], increased tumor-infiltrating lymphocytes (TIL) [9,10,11], elevated PD-1/PD-L1 expression [2,12,13,14], and IFN-γ signature [15,16] have been generally correlated with improved immunotherapy responses [11,17]. The gene discussed is CD274; the disease is neoplasm.